| Symbol | ALEC |
|---|---|
| Name | ALECTOR, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 131 OYSTER POINT BLVD.,SUITE 600, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 415 231-5660 |
| Fax | — |
| — | |
| Website | https://www.alector.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Alector Inc is a clinical stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies which are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline product inlcude AL001, AL002, AL003, and AL101. Additional info from NASDAQ: |
Wong-Sarad Grace 🔴 sold 1.8K shares of Alector, Inc. (ALEC) at $2.65 Transaction Date: Apr 16, 2026 | Filing ID: 161848
Read more📋 GRACE WONG-SARAD (Officer) plans to sell 2K shares of ALECTOR, INC. (at $2.65 each, total $5K) Filed: Apr 16, 2026 | ID: 003574
Read moreNew Form SCHEDULE 13G/A - Alector, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000550 <b>Size:</b> 7 KB
Read moreBerkley Neil Lindsay 🟢 acquired 54.6K shares of Alector, Inc. (ALEC) Transaction Date: Mar 13, 2026 | Filing ID: 106246
Read moreWong-Sarad Grace 🔴 sold 1.0K shares of Alector, Inc. (ALEC) at $2.65 Transaction Date: Mar 10, 2026 | Filing ID: 104633
Read moreNew Form S-3 - Alector, Inc. <b>Filed:</b> 2026-03-12 <b>AccNo:</b> 0001193125-26-104120 <b>Size:</b> 599 KB
Read moreWong-Sarad Grace 🔴 sold 3.4K shares of Alector, Inc. (ALEC) at $2.08 Transaction Date: Mar 03, 2026 | Filing ID: 000004
Read more📋 GRACE WONG-SARAD (Officer) plans to sell 3K shares of ALECTOR, INC. (at $2.08 each, total $7K) Filed: Mar 03, 2026 | ID: 002123
Read moreRosenthal Arnon 🔴 sold 81.9K shares of Alector, Inc. (ALEC) at $2.12 Transaction Date: Mar 02, 2026 | Filing ID: 000002
Read moreBerkley Neil Lindsay 🔴 sold 29.6K shares of Alector, Inc. (ALEC) at $2.12 Transaction Date: Mar 02, 2026 | Filing ID: 000002
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07105709 | Open-label Extension Study in Participants With Early Alzheimer's Disease | Phase2 | Alzheimer's Disease | Recruiting | 2025-08-14 | 2028-12-08 | ClinicalTrials.gov |
| NCT06111014 | Continuation Study for Latozinemab | Phase3 | Neurodegenerative Diseases | Terminated | 2023-12-08 | 2026-01-07 | ClinicalTrials.gov |
| NCT06079190 | Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer'… | Phase2 | Alzheimer's Disease | Active_Not_Recruiting | 2023-10-20 | 2026-11-23 | ClinicalTrials.gov |
| NCT05744401 | A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of A… | Phase2 | Alzheimer's Disease | Terminated | 2023-01-04 | 2025-02-05 | ClinicalTrials.gov |
| NCT05053035 | A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS | Phase2 | Amyotrophic Lateral Sclerosis | Terminated | 2021-09-02 | 2022-10-28 | ClinicalTrials.gov |
| NCT04592874 | A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With E… | Phase2 | Alzheimer Disease | Completed | 2021-01-22 | 2024-09-12 | ClinicalTrials.gov |
| NCT04111666 | A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101 | Phase1 | Healthy | Completed | 2019-12-14 | 2022-06-09 | ClinicalTrials.gov |
| NCT03822208 | First in Human Study for Safety and Tolerability of AL003. | Phase1 | Healthy | Completed | 2019-03-29 | 2021-05-06 | ClinicalTrials.gov |
| NCT03635047 | A Phase I Study for Safety and Tolerability of AL002. | Phase1 | Healthy | Completed | 2018-11-12 | 2020-11-25 | ClinicalTrials.gov |
| NCT03636204 | A First in Human Study in Healthy Volunteers and in Participants With Frontotem… | Phase1 | Healthy | Completed | 2018-09-14 | 2019-12-31 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Latozinemab | DRUG | Phase PHASE3 | Neurodegenerative Diseases | TERMINATED | NCT06111014 |
| GSK4527226 | DRUG | Phase PHASE2 | Alzheimer's Disease | RECRUITING | NCT07105709 |
| Open label - AL001 | DRUG | Phase PHASE3 | Frontotemporal Dementia | TERMINATED | NCT04374136 |
| AL101 | BIOLOGICAL | Phase PHASE1 | Healthy | COMPLETED | NCT04111666 |
| AL003 | BIOLOGICAL | Phase PHASE1 | Healthy | COMPLETED | NCT03822208 |
| Placebo | OTHER | Phase PHASE2 | Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT06079190 |
| AL001 | DRUG | Phase PHASE2 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT05053035 |
| Saline Solution | OTHER | Phase PHASE1 | Healthy | COMPLETED | NCT03822208 |
| AL002 | DRUG | Phase PHASE2 | Alzheimer's Disease | TERMINATED | NCT05744401 |